Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 30:12:781668.
doi: 10.3389/fpsyt.2021.781668. eCollection 2021.

Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder

Affiliations
Review

Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder

Vikrant R Mahajan et al. Front Psychiatry. .

Abstract

Alcohol use disorder (AUD) is a chronic, relapsing brain disorder, characterized by compulsive alcohol seeking and disrupted brain function. In individuals with AUD, abstinence from alcohol often precipitates withdrawal symptoms than can be life threatening. Here, we review evidence for nutritional ketosis as a potential means to reduce withdrawal and alcohol craving. We also review the underlying mechanisms of action of ketosis. Several findings suggest that during alcohol intoxication there is a shift from glucose to acetate metabolism that is enhanced in individuals with AUD. During withdrawal, there is a decline in acetate levels that can result in an energy deficit and could contribute to neurotoxicity. A ketogenic diet or ingestion of a ketone ester elevates ketone bodies (acetoacetate, β-hydroxybutyrate and acetone) in plasma and brain, resulting in nutritional ketosis. These effects have been shown to reduce alcohol withdrawal symptoms, alcohol craving, and alcohol consumption in both preclinical and clinical studies. Thus, nutritional ketosis may represent a unique treatment option for AUD: namely, a nutritional intervention that could be used alone or to augment the effects of medications.

Keywords: alcohol dependence; alcohol metabolism; alcohol withdrawal; alcoholism; ketogenic diet; ketone ester.

PubMed Disclaimer

Conflict of interest statement

HK is named as an inventor on PCT patent application #15/878,640 entitled: Genotypeguided dosing of opioid agonists, filed January 24, 2018. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Hepatic metabolism of ethanol and fatty acids and ketogenesis are shown. (B) Non-hepatic metabolism of D-BHB, acetate, and glucose in the cytosol and mitochondria converge on acetyl-CoA which enters the tricarboxylic acid (TCA) cycle. Within neurons, acetoacetate and D-BHB are transported into the mitochondria via monocarboxylate transporters. Abbreviations: TCA Cycle, tricarboxylic acid cycle/the citric acid cycle/Kreb's cycle; D-BHB, D-β-Hydroxybutyrate; NAD(H), nicotinamide adenine dinucleotide; SCOT, 3-ketoacid CoA transferase; ACAT, acetyl-CoA acetyltransferase; I, NADH ubiquinone oxireductase; II, succinate dehydrogenase; III, CoQH2-cytochrome c reductase; IV, cytochrome c oxidase; ATP Synthase, FOF1 ATP synthase; PDC, pyruvate dehydrogenase complex.
Figure 2
Figure 2
Schematic overview of the shift from high acetate utlization to low brain acetate avaliability with slow recovery of brain glucose metabolism in chronic AUD during detoxification. This shift is hypothesized to produce a central energy deficit that could contribute to alcohol withdrawal symptoms and associated neurotoxicity.

References

    1. Saitz R, O'malley SS. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am. (1997) 81:881–907. 10.1016/S0025-7125(05)70554-X - DOI - PubMed
    1. Day E, Daly C. Clinical management of the alcohol withdrawal syndrome. Addiction. (2021). 10.1111/add.15647. [Epub ahead of print]. - DOI - PubMed
    1. Morel A, Grall-Bronnec M, Bulteau S, Chauvin-Grelier P, Gailledrat L, Pinot ML, et al. . Benzodiazepine dependence in subjects with alcohol use disorders: what prevalence? Expert Opin Drug Saf. (2016) 15:1313–9. 10.1080/14740338.2016.1221922 - DOI - PubMed
    1. Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. (2014) 75:79–88. 10.15288/jsads.2014.s17.79 - DOI - PMC - PubMed
    1. Cheng YC, Huang YC, Huang WL. Gabapentinoids for treatment of alcohol use disorder: a systematic review and meta-analysis. Hum Psychopharmacol. (2020) 35:1–11. 10.1002/hup.2751 - DOI - PubMed

LinkOut - more resources